Envoy Medical

Envoy Medical FCF Margin

The Free Cash Flow Margin of Envoy Medical (COCH) as of Nov 2, 2026 is -7,626.56 %. In the previous year, Free Cash Flow Margin was -8,412.89 % — a change of -9.35% (higher).

FCF Margin

-7,626.56 %

YoY

-9.35%

Last updated:

Free Cash Flow Margin of Envoy Medical is 2025 -7,626.56 % . Free Cash Flow Margin of Envoy Medical was 2024 -8,412.89 % . It decreases by -9.35% higher compared to the previous year.

The Envoy Medical FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2021
-2,277.74 USD
Jan 1, 2022
-3,807.17 USD
Jan 1, 2023
-5,456.96 USD
Jan 1, 2024
-8,412.89 USD
Jan 1, 2025
-7,626.56 USD
The Envoy Medical FCF Margin history
YEARFCF MarginYoY
-7,626.56 %-9.35%
-8,412.89 %+54.17%
-5,456.96 %+43.33%
-3,807.17 %+67.15%
-2,277.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Envoy Medical Stock analysis

What does Envoy Medical do? Envoy Medical Inc generates revenue through its portfolio of hearing health solutions including hearing aids, middle ear implants, bone conduction devices, and cochlear implants. The company's Esteem is a fully implanted active middle ear implant targeting adults with moderate to severe sensorineural hearing loss. Bone conduction devices feature an external component paired with a surgically implanted fixture behind the ear, offering amplification without ear molds. Hearing aids serve patients with mild to moderate hearing loss, while cochlear implants address moderate-to-profound sensorineural hearing loss. These products are sold to healthcare providers and patients seeking advanced hearing solutions within the hearing loss spectrum. The company's business model focuses on providing medical technologies that shift industry paradigms, with products designed for different severity levels of hearing loss. Hearing aids target mild to moderate cases, while cochlear implants and Esteem address more severe conditions. Bone conduction devices specifically eliminate the need for ear molds by using bone conduction technology. All solutions are positioned to serve both providers and patients requiring specialized hearing devices across the hearing loss spectrum. Envoy Medical Inc's revenue streams come from direct sales of its hearing devices to healthcare providers who then serve patients. The company's product range spans from non-invasive hearing aids for mild cases to fully implanted solutions like Esteem for severe hearing loss. Each product category targets specific patient segments based on hearing loss severity, ensuring tailored solutions for different needs within the hearing health market. Envoy Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Envoy Medical stock

Free Cash Flow Margin of Envoy Medical is -7,626.56 % in 2025.

Free Cash Flow Margin of Envoy Medical changed from -8,412.89 % to -7,626.56 %, representing a -9.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Envoy Medical since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Envoy Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Envoy Medical

All Key Metrics — Envoy Medical